Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals executive Edward Atkinson has filed a notice of proposed share sales under Rule 144. The filing covers the planned sale of 2,031 shares of Vertex common stock through Fidelity Brokerage Services LLC on or about 02/17/2026 on NASDAQ, with an aggregate market value of 994093.26 at the time of the notice.
The 2,031 shares to be sold were acquired on 02/13/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Atkinson has already sold 2,500 Vertex common shares on 11/17/2025 for gross proceeds of 1086450.00, and 1,751 shares on 02/11/2026 for gross proceeds of 806212.93. The filing also notes that the seller represents not being aware of undisclosed material adverse information about the company.
Vertex Pharmaceuticals describes a broad rare-disease and specialty portfolio in its annual report, led by cystic fibrosis medicines, the gene-editing therapy CASGEVY for severe sickle cell disease and transfusion‑dependent beta thalassemia, and JOURNAVX for moderate‑to‑severe acute pain in adults.
The company highlights a deep late‑stage pipeline, including povetacicept for IgA nephropathy and primary membranous nephropathy, inaxaplin for APOL1‑mediated kidney disease, zimislecel cell therapy for type 1 diabetes, and suzetrigine for diabetic peripheral neuropathic pain. Vertex reports strong global commercialization, extensive intellectual‑property protection, and ongoing investment in manufacturing capacity and strategic deals such as the Alpine acquisition.
A shareholder filed a notice of proposed sale of 988 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or about 02/13/2026 on NASDAQ. The filing notes that 253,718,831 shares of the class were outstanding.
The shares to be sold were acquired via restricted stock vesting from the issuer as compensation, with 347 shares vesting on 10/01/2025 and 641 shares vesting on 02/10/2026. The shareholder, Jonathan Biller, previously sold 347 shares on 12/03/2025 for gross proceeds of 155,803.00 and 1,925 shares on 02/11/2026 for gross proceeds of 886,327.75.
Vertex Pharmaceuticals has an insider planning a modest stock sale. A person associated with Vertex intends to sell 266 shares of common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of 133000.00, around 02/13/2026.
The 266 shares were acquired on 05/01/2024 through restricted stock vesting as compensation from the issuer. Vertex had 253,718,831 shares of common stock outstanding, which is a baseline figure for the company’s total share count.
Vertex Pharmaceuticals shareholder Ourania Tatsis filed a Form 144 notice to sell 1,500 shares of Vertex common stock, with an aggregate market value of $749,992.02, through Fidelity Brokerage Services on NASDAQ around February 13, 2026.
The filing indicates 253,718,831 Vertex common shares outstanding. The 1,500 shares to be sold trace to restricted stock that vested as compensation in February 2021, in lots of 1,448 and 52 shares acquired from the issuer.
Over the past three months, Tatsis has sold additional Vertex common shares, including 4,500 shares on December 3, 2025 for gross proceeds of $2,024,955.40, 4,500 shares on January 7, 2026 for $2,137,455.00, and 466 shares on February 11, 2026 for $214,560.38.
Vertex Pharmaceuticals executive Charles F. Wagner Jr. reported a tax-related share disposition. On February 10, 2026, he transferred 3,045 shares of Vertex common stock at $468.41 per share under code F, which reflects payment of tax liability by delivering shares.
After this transaction, Wagner directly beneficially owned 48,280 shares of Vertex common stock. The filing characterizes the move as a tax-withholding disposition rather than an open-market purchase or sale.
Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions. On February 11, 2026, she executed an open-market sale of 466 shares of common stock at $460.43 per share, leaving her with 51,436 directly owned shares.
On February 10, 2026, 2,140 shares were disposed of at $468.41 per share to cover tax obligations, a transaction coded as F. The sale was made under a company-approved Rule 10b5-1 trading plan that was entered into on August 21, 2025.
Vertex Pharmaceuticals executive Amit Sachdev reported a tax-related share disposition. On 02/10/2026, 2,057 shares of Vertex common stock were disposed of in a tax-withholding transaction at $468.41 per share. After this, he held 68,941 shares directly.
He also reported indirect ownership of 882 shares through a 401(k) plan and 9,301 shares held in a trust. The filing reflects equity compensation and related tax withholding rather than an open-market trade.
Vertex Pharmaceuticals executive reports tax-withholding share disposition. EVP and Chief Commercial Officer McKechnie Duncan transferred 1,127 shares of Vertex common stock on February 10, 2026 in a tax-withholding disposition priced at $468.41 per share, used to cover tax obligations related to equity compensation.
After this transaction, Duncan directly beneficially owned 21,811 shares of Vertex common stock. The transaction is coded "F," indicating payment of an exercise price or tax liability by delivering already-owned securities rather than an open-market sale.
Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported an automatic share disposition related to taxes. On 02/10/2026, 8,297 shares of Vertex common stock were disposed of at $468.41 per share in a transaction coded "F", which indicates payment of a tax liability by delivering shares rather than a market trade. After this tax-withholding transaction, she directly beneficially owned 146,528 shares of Vertex common stock.